Last Updated January 2018 - AAACEUS.com · 2018-09-05 · nonmedical use of all prescription drugs, including pain relievers, sedatives, and stimulants. Among nonmedical users of

1

NationalInstituteonDrugAbuse(NIDA)

MisuseofPrescriptionDrugs

LastUpdatedJanuary2018

https://www.drugabuse.gov

2

TableofContents

MisuseofPrescriptionDrugs

Summary

Whatisthescopeofprescriptiondrugmisuse?

Howmanypeoplesufferadversehealthconsequencesfrommisuseofprescriptiondrugs?

Isitsafetouseprescriptiondrugsincombinationwithothermedications?

Whichclassesofprescriptiondrugsarecommonlymisused?

Areprescriptiondrugssafetotakewhenpregnant?

Howcanprescriptiondrugmisusebeprevented?

Howcanprescriptiondrugaddictionbetreated?

WherecanIgetfurtherinformationaboutprescriptiondrugmisuse?

References

3

Summary

Misuseofprescriptiondrugsmeanstakingamedicationinamannerordoseotherthanprescribed;takingsomeoneelse’sprescription,evenifforalegitimatemedicalcomplaintsuchaspain;ortakingamedicationtofeeleuphoria(i.e.,togethigh).*Thetermnonmedicaluseofprescriptiondrugsalsoreferstothesecategoriesofmisuse.Thethreeclassesofmedicationmostcommonlymisusedare :

opioids—usuallyprescribedtotreatpain

centralnervoussystem[CNS]depressants(thiscategoryincludestranquilizers,sedatives,andhypnotics)—usedtotreatanxietyandsleepdisorders

stimulants—mostoftenprescribedtotreatattention-deficithyperactivitydisorder(ADHD)

Prescriptiondrugmisusecanhaveseriousmedicalconsequences.Increasesinprescriptiondrugmisuse overthelast15yearsarereflectedinincreasedemergencyroomvisits,overdosedeathsassociatedwithprescriptiondrugs ,andtreatmentadmissionsforprescriptiondrugusedisorders,themostsevereformofwhichisaddiction.Amongthosewhoreportedpast-yearnonmedicaluseofaprescriptiondrug,nearly12percentmetcriteriaforprescriptiondrugusedisorder. Unintentionaloverdosedeathsinvolvingopioidpainrelievers

©iStock.com/ognianm

1

2

3–6

1

4

havemorethanquadrupledsince1999andhaveoutnumberedthoseinvolvingheroinandcocainesince2002.

*Takingprescriptiondrugstogethighissometimescalled"prescriptiondrugabuse."

7

5

Whatisthescopeofprescriptiondrugmisuse?

Misuseofprescriptionopioids,centralnervoussystem(CNS)depressants,andstimulantsisaseriouspublichealthproblemintheUnitedStates.Althoughmostpeopletakeprescriptionmedicationsresponsibly,anestimated54millionpeople(morethan20percentofthoseaged12andolder)haveusedsuchmedicationsfornonmedicalreasonsatleastonceintheirlifetime. Accordingtoresultsfromthe2014NationalSurveyonDrugUseandHealth,anestimated2.1millionAmericansusedprescriptiondrugsnonmedicallyforthefirsttimewithinthepastyear,whichaveragestoapproximately5,750initiatesperday.Fifty-fourpercentwerefemalesandabout30percentwereadolescents.

Thereasonsforthehighprevalenceofprescriptiondrugmisusevarybyage,gender,andotherfactors,butlikelyincludeeaseofaccess. Thenumberofprescriptionsforsomeofthesemedicationshasincreaseddramaticallysincetheearly1990s. Moreover,misinformationabouttheaddictivepropertiesofprescriptionopioidsandtheperceptionthatprescriptiondrugsarelessharmfulthanillicitdrugsareotherpossiblecontributorstotheproblem.

AlthoughmisuseofprescriptiondrugsaffectsmanyAmericans,certainpopulationssuchasyouth,olderadults,andwomenmaybeatparticularrisk.Inaddition,whilemorementhanwomencurrentlymisuseprescriptiondrugs,

theratesofmisuseandoverdoseamongwomenareincreasingfasterthanamongmen.

AdolescentsandYoungAdults

Nonmedicaluseofprescriptiondrugsishighestamongyoungadultsaged18to25,with4.6percentreportingnonmedicaluseinthepastmonth.Amongyouthaged12to17,1.6percentreportedpast-monthnonmedicaluseofprescriptionmedications.

Afteralcohol,marijuana,andtobacco,prescriptiondrugs(takennonmedically)

1

1

8

9

10,11

12–

14

1

6

areamongthemostcommonlyuseddrugsby12thgraders.TheNIDA’sMonitoringtheFuturesurveyofsubstanceuseandattitudesinteensfoundthatabout6percentofhighschoolseniorsreportedpast-yearnonmedicaluseoftheprescriptionstimulantAdderall in2017,and2percentreportedmisusingtheopioidpainrelieverVicodin .

Althoughpast-yearnonmedicaluseofCNSdepressantsandopioidpainrelieversdecreasedamong12thgradersbetween2011and2015,thisisnotthecaseforthenonmedicaluseofstimulants.NonmedicaluseofAdderallincreasedbetween2009and2013buthassinceappearedtodecline. Whenaskedhowtheyobtainedprescriptionstimulantsfornonmedicaluse,morethanhalfoftheadolescentsandyoungadultssurveyedsaidtheyeitherboughtorreceivedthedrugsfromafriendorrelative.Interestingly,thenumberwhopurchasedthesedrugsthroughtheinternetwasnegligible.

Youthwhomisuseprescriptionmedicationsarealsomorelikelytoreportuseofotherdrugs.Multiplestudieshaverevealedassociationsbetweenprescriptiondrugmisuseandhigherratesofcigarettesmoking;heavyepisodicdrinking;andmarijuana,cocaine,andotherillicitdruguseamongU.S.adolescents,youngadults,andcollegestudents. Inthecaseofprescriptionopioids,medicaluseisalsoassociatedwithagreaterriskoffutureopioidmisuse,particularlyinadolescentswhodisapproveofillegaldruguseandhavelittletonohistoryofdruguse.

®

® 15

®

15

1

16–19

14

7

OlderAdults

Morethan80percentofolderpatients(aged57to85years)useatleastoneprescriptionmedicationonadailybasis,withmorethan50percenttakingmorethanfivemedicationsorsupplementsdaily. Thiscanpotentiallyleadtohealthissuesresultingfromunintentionallyusingaprescriptionmedicationinamannerotherthanhowitwasprescribed,orfromintentionalnonmedicaluse.Thehighratesofmultiple(comorbid)chronicillnessesinolderpopulations,age-relatedchangesindrugmetabolism,andthepotentialfordruginteractionsmakesmedication(andothersubstance)misusemoredangerousinolderpeoplethaninyoungerpopulations. Further,alargepercentageofolderadultsalsouseover-the-countermedicinesanddietarysupplements,which(inadditiontoalcohol)couldcompoundanyadversehealthconsequencesresultingfromnonmedicaluseofprescriptiondrugs.

Women

Source:McCabeetal.,2012

12

20

12

8

Overall,moremalesthanfemalesmisuseprescriptiondrugsinallagegroupsexceptadolescence(12to17years);adolescentgirlsexceedboysinthenonmedicaluseofallprescriptiondrugs,includingpainrelievers,sedatives,andstimulants.Amongnonmedicalusersofprescriptiondrugs,females12to17yearsoldarealsomorelikelytomeetsubstanceusedisordercriteriaforprescriptiondrugs. Additionally,whilemorementhanwomendieofprescriptionopioidoverdose,therateofoverdoseisincreasingmoresharplyinwomenthaninmen.

21

22

9

Howmanypeoplesufferadversehealthconsequencesfrommisuseofprescriptiondrugs?

TheDrugAbuseWarningNetwork(DAWN)monitoredemergencydepartment(ED)visitsinselectedareasacrosstheNationthrough2011.DAWNreportedthatmorethan1.2millionEDvisitsin2011couldbeattributedtononmedicaluseofprescriptiondrugs;thisrepresentsabouthalf(50.5percent)ofallEDvisitsrelatedtodrugmisuse.Roughly488,000,or39.2percent,oftheseEDvisitsinvolvedprescriptionopioidpainrelievers,aratenearlytriplethatof6yearsprior.EDvisitsalsomorethanquadrupledforcentralnervoussystem(CNS)stimulantstonearly41,000visitsin2011andincreased138percentforCNSdepressantsto422,000visits.Ofthelatter,85percentinvolvedbenzodiazepines(e.g.,Xanax ).EDvisitsrelatedtouseofzolpidem(Ambien ),apopularprescribednon-benzodiazepinesleepaid,rosefromroughly13,000in2004to30,000in2011.MorethanhalfofEDvisitsfornonmedicaluseofprescriptiondrugsinvolvedmultipledrugs. Analysisofhospitalinpatientdataalsorevealeda72percentincreaseinhospitalizationsrelatedtoopioiduseoverthedecadefrom2002to2012,includingincreasesinseriousinfectionassociatedwithintravenousdrugadministration.Inpatientcostsforthesehospitalizationsquadrupledoverthesametimeperiod.

® ®

4

23

10

Isitsafetouseprescriptiondrugsincombinationwithothermedications?

Thesafetyofusingprescriptiondrugsincombinationwithothersubstancesdependsonanumberoffactorsincludingthetypesofmedications,dosages,othersubstanceuse(e.g.,alcohol),andindividualpatienthealthfactors.Patientsshouldtalkwiththeirhealthcareprovideraboutwhethertheycansafelyusetheirprescriptiondrugswithothersubstances,includingprescriptionandover-the-counter(OTC)medicationsaswellasalcohol,tobacco,andillicitdrugs.Specifically,drugsthatslowdownbreathingrate,suchasopioids,alcohol,antihistamines,prescriptioncentralnervoussystemdepressants(includingbarbituratesandbenzodiazepines),orgeneralanesthetics,shouldnotbetakentogetherbecausethesecombinationsincreasetheriskoflife-threateningrespiratorydepression. Stimulantsshouldalsonotbeusedwithothermedicationsunlessrecommendedbyaphysician.PatientsshouldbeawareofthedangersassociatedwithmixingstimulantsandOTCcoldmedicinesthatcontaindecongestants,ascombiningthesesubstancesmaycausebloodpressuretobecomedangerouslyhighorleadtoirregularheartrhythms.

©Shutterstock/DavidSmart

5,24

25

11

Whichclassesofprescriptiondrugsarecommonlymisused?

Opioids

Whatareopioids?

Opioidsaremedicationsthatactonopioidreceptorsinboththespinalcordandbraintoreducetheintensityofpain-signalperception.Theyalsoaffectbrainareasthatcontrolemotion,whichcanfurtherdiminishtheeffectsofpainfulstimuli.Theyhavebeenusedforcenturiestotreatpain,cough,anddiarrhea. Themostcommonmodernuseofopioidsistotreatacutepain.However,sincethe1990s,theyhavebeenincreasinglyusedtotreatchronicpain,despitesparseevidencefortheireffectivenesswhenusedlongterm. Indeed,somepatientsexperienceaworseningoftheirpainorincreasedsensitivitytopainasaresultoftreatmentwithopioids,aphenomenonknownashyperalgesia. Importantly,inadditiontorelievingpain,opioidsalsoactivaterewardregionsinthebraincausingtheeuphoria—orhigh—thatunderliesthepotentialformisuseandaddiction.Chemically,thesemedicationsareverysimilartoheroin,whichwasoriginallysynthesizedfrommorphineasapharmaceuticalinthelate19thcentury. Thesepropertiesconferanincreasedriskofaddictionandoverdoseeveninpatientswhotaketheirmedicationasprescribed.

Prescriptionopioidmedicationsincludehydrocodone(e.g.,Vicodin ),oxycodone(e.g.,OxyContin ,Percocet ),oxymorphone(e.g.,Opana ),morphine(e.g.,Kadian ,Avinza ),codeine,fentanyl,andothers.HydrocodoneproductsarethemostcommonlyprescribedintheUnitedStatesforavarietyofindications,includingdental-andinjury-relatedpain. Oxycodoneandoxymorphonearealsoprescribedformoderatetoseverepainrelief. Morphineisoftenusedbeforeandaftersurgicalprocedurestoalleviateseverepain,andcodeineistypicallyprescribedformilderpain. Inadditiontotheirpain-relievingproperties,someofthesedrugs—codeineanddiphenoxylate(Lomotil ),forexample—areusedto

26

27

28

29

27

®

® ® ®

® ®

30

31,32

26

®

26

12

relievecoughsandseverediarrhea.

Howdoopioidsaffectthebrainandbody?

Opioidsactbyattachingtoandactivatingopioidreceptorproteins,whicharefoundonnervecellsinthebrain,spinalcord,gastrointestinaltract,andotherorgansinthebody. Whenthesedrugsattachtotheirreceptors,theyinhibitthetransmissionofpainsignals.Opioidscanalsoproducedrowsiness,mentalconfusion,nausea,constipation,andrespiratorydepression,andsincethesedrugsalsoactonbrainregionsinvolvedinreward,theycaninduceeuphoria,particularlywhentheyaretakenatahigher-than-prescribeddoseoradministeredinotherwaysthanintended. Forexample,OxyContin isanoralmedicationusedtotreatmoderatetoseverepainthroughaslow,steadyreleaseoftheopioid.SomepeoplewhomisuseOxyContin intensifytheirexperiencebysnortingorinjectingit. Thisisaverydangerouspractice,greatlyincreasingtheperson’sriskforseriousmedicalcomplications,includingoverdose.

26

26

26 ®

®

†33

13

UnderstandingDependence,Addiction,andTolerance

Dependenceoccursasaresultofphysiologicaladaptationstochronicexposuretoadrug.Itisoftenapartofaddiction,buttheyarenotequivalent.Addictioninvolvesotherchangestobraincircuitryandisdistinguishedbycompulsivedrugseekingandusedespitenegativeconsequences.

Thosewhoaredependentonamedicationwillexperienceunpleasantphysicalwithdrawalsymptomswhentheyabruptlyreduceorstopuseofthedrug.Thesesymptomscanbemildtosevere(dependingonthedrug)andcanusuallybemanagedmedicallyoravoidedbyslowlytaperingdownthedrugdosage.

Tolerance,ortheneedtotakehigherdosesofamedicationtogetthesameeffect,oftenaccompaniesdependence.Whentoleranceoccurs,itcanbedifficultforaphysiciantoevaluatewhetherapatientisdevelopingadrugproblemorhasamedicalneedforhigherdosestocontrolhisorhersymptoms.Forthisreason,physiciansshouldbevigilantandattentivetotheirpatients’symptomsandleveloffunctioningandshouldscreenforsubstancemisusewhentoleranceordependenceispresent.

Whatarethepossibleconsequencesofprescriptionopioidmisuse?

34

35

27

14

Whentakenasprescribed,patientscanoftenuseopioidstomanagepainsafelyandeffectively.However,itispossibletodevelopasubstanceusedisorderwhentakingopioidmedicationsasprescribed.Thisriskandtheriskforoverdoseincreasewhenthesemedicationsaremisused.Evenasinglelargedoseofanopioidcancausesevererespiratorydepression(slowingorstoppingofbreathing),whichcanbefatal;takingopioidswithalcoholorsedativesincreasesthisrisk.

Whenproperlymanaged,short-termmedicaluseofopioidpainrelievers—takenforafewdaysfollowingoralsurgery,forinstance—rarelyleadstoanopioidusedisorderoraddiction.Butregular(e.g.,severaltimesaday,forseveralweeksormore)orlonger-termuseofopioidscanleadtodependence(physicaldiscomfortwhennottakingthedrug),tolerance(diminishedeffectfromtheoriginaldose,leadingtoincreasingtheamounttaken),and,insomecases,addiction(compulsivedrugseekinganduse)(see"UnderstandingDependence,Addiction,andTolerance").Withbothdependenceandaddiction,withdrawalsymptomsmayoccurifdruguseissuddenlyreducedorstopped.Thesesymptomsmayincluderestlessness,muscleandbonepain,insomnia,diarrhea,vomiting,coldflasheswithgoosebumps,andinvoluntarylegmovements.

Misuseofprescriptionopioidsisalsoariskfactorfortransitioningtoheroinuse.Readmoreabouttherelationshipbetweenprescriptionopioidsand

©iStock.com/Sezeryadigar

5,24

29

15

heroinintheNIDA'sPrescriptionOpioidsandHeroinResearchReport.

Howisprescriptionopioidmisuserelatedtochronicpain?

Healthcareprovidershavelongwrestledwithhowbesttotreatthemorethan100millionAmericanswhosufferfromchronicpain. Opioidshavebeenthemostcommontreatmentforchronicpainsincethelate1990s,butrecentresearchhascastdoubtbothontheirsafetyandtheirefficacyinthetreatmentofchronicpainwhenitisnotrelatedtocancerorpalliativecare. Thepotentialrisksinvolvedwithlong-termopioidtreatment,suchasthedevelopmentofdrugtolerance,hyperalgesia,andaddiction,presentdoctorswithadilemma,asthereislimitedresearchonalternativetreatmentsforchronicpain.Patientsthemselvesmayevenbereluctanttotakeanopioidmedicationprescribedtothemforfearofbecomingaddicted.

Estimatesoftherateofopioidaddictionamongchronicpainpatientsvaryfromabout3percentupto26percent.Thisvariabilityistheresultofdifferencesintreatmentduration,insufficientresearchonlong-termoutcomes,anddisparatestudypopulationsandmeasuresusedtoassessnonmedicaluseoraddiction.

Tomitigateaddictionrisk,physiciansshouldadheretotheCDCGuidelineforPrescribingOpioidsforChronicPain.Beforeprescribing,physiciansshouldassesspainandfunctioning,considerifnon-opioidtreatmentoptionsareappropriate,discussatreatmentplanwiththepatient,evaluatethepatient’sriskofharmormisuse,andcoprescribenaloxonetomitigatetheriskforoverdose(seetheNIDA'swebpageonnaloxone).Whenfirstprescribingopioids,physiciansshouldgivethelowesteffectivedosefortheshortesttherapeuticduration.Astreatmentcontinues,thepatientshouldbemonitoredatregularintervals,andopioidtreatmentshouldbecontinuedonlyifmeaningfulclinicalimprovementsinpainandfunctioningareseenwithoutharm.

Changingtherouteofadministrationcanalsobeafeatureofthemisuse

36

27

37

27

†

16

ofotherprescriptionmedications,includingstimulants,apracticethatcanleadtoseriousmedicalconsequences.

CNSDepressants

WhatareCNSdepressants?

Centralnervoussystem(CNS)depressants,acategorythatincludestranquilizers,sedatives,andhypnotics,aresubstancesthatcanslowbrainactivity.Thispropertymakesthemusefulfortreatinganxietyandsleepdisorders.Thefollowingareamongthemedicationscommonlyprescribedforthesepurposes :

Benzodiazepines,suchasdiazepam(Valium ),clonazepam(Klonopin ),andalprazolam(Xanax ),aresometimesprescribedtotreatanxiety,acutestressreactions,andpanicattacks.Clonazepammayalsobeprescribedtotreatseizuredisorders.Themoresedatingbenzodiazepines,suchastriazolam(Halcion )andestazolam(Prosom )areprescribedforshort-termtreatmentofsleepdisorders.Usually,benzodiazepinesarenotprescribedforlong-termusebecauseofthehighriskfordevelopingtolerance,dependence,oraddiction.

Non-benzodiazepinesleepmedications,suchaszolpidem(Ambien ),eszopiclone(Lunesta ),andzaleplon(Sonata ),knownasz-drugs,haveadifferentchemicalstructurebutactonthesameGABAtypeAreceptorsinthebrainasbenzodiazepines.Theyarethoughttohavefewersideeffectsandlessriskofdependencethanbenzodiazepines.

Barbiturates,suchasmephobarbital(Mebaral ),phenobarbital(Luminal ),andpentobarbitalsodium(Nembutal ),areusedlessfrequentlytoreduceanxietyortohelpwithsleepproblemsbecauseoftheirhigherriskofoverdosecomparedtobenzodiazepines.However,theyarestillusedinsurgicalproceduresandtotreatseizuredisorders.

HowdoCNSdepressantsaffectthebrainandbody?

38

®

® ®

®

®

®

® ®

®

® ®

17

MostCNSdepressantsactonthebrainbyincreasingactivityatreceptorsfortheinhibitoryneurotransmittergamma-aminobutyricacid(GABA).Althoughthedifferentclassesofdepressantsworkinuniqueways,itisthroughtheirabilitytoincreaseGABAsignaling—therebyincreasinginhibitionofbrainactivity—thattheyproduceadrowsyorcalmingeffectthatismedicallybeneficialtothosesufferingfromanxietyorsleepdisorders.

WhatarethepossibleconsequencesofCNSdepressantmisuse?

Despitetheirbeneficialtherapeuticeffects,benzodiazepinesandbarbiturateshavethepotentialformisuseandshouldbeusedonlyasprescribed. Theuseofnon-benzodiazepinesleepaids,orz-drugs,islesswell-studied,butcertainindicatorshaveraisedconcernabouttheirpsychoactivepropertiesaswell.

Duringthefirstfewdaysoftakingadepressant,apersonusuallyfeelssleepyanduncoordinated,butasthebodybecomesaccustomedtotheeffectsofthedrugandtolerancedevelops,thesesideeffectsbegintodisappear.Ifoneusesthesedrugslongterm,heorshemayneedlargerdosestoachievethetherapeuticeffects.Continuedusecanalsoleadtodependenceandwithdrawalwhenuseisabruptlyreducedorstopped(see"UnderstandingDependence,Addiction,andTolerance").Becauseallsedativesworkbyslowingthebrain’sactivity,whenanindividualstopstakingthem,therecanbeareboundeffect,resultinginseizuresorotherharmfulconsequences.

Althoughwithdrawalfrombenzodiazepinescanbeproblematic,itisrarelylifethreatening,whereaswithdrawalfromprolongeduseofbarbituratescanhavelife-threateningcomplications. Therefore,someonewhoisthinkingaboutdiscontinuingasedativeorwhoissufferingwithdrawalfromCNSdepressantsshouldspeakwithaphysicianorseekimmediatemedicaltreatment.

38

38

39

38

40

18

Stimulants

Whatarestimulants?

Stimulantsincreasealertness,attention,andenergy,aswellaselevatebloodpressure,heartrate,andrespiration.Historically,stimulantswereusedtotreatasthmaandotherrespiratoryproblems,obesity,neurologicaldisorders,andavarietyofotherailments.Butastheirpotentialformisuseandaddictionbecameapparent,thenumberofconditionstreatedwithstimulantshasdecreased. Now,stimulantsareprescribedforthetreatmentofonlyafewhealthconditions,includingattention-deficithyperactivitydisorder(ADHD),narcolepsy,andoccasionallytreatment-resistantdepression.

Howdostimulantsaffectthebrainandbody?

Stimulants,suchasdextroamphetamine(Dexedrine ,Adderall )andmethylphenidate(Ritalin ,Concerta ),actinthebrainonthefamilyofmonoamineneurotransmittersystems,whichincludenorepinephrineanddopamine.Stimulantsenhancetheeffectsofthesechemicals.Anincreaseindopaminesignalingfromnonmedicaluseofstimulantscaninduceafeelingofeuphoria,andthesemedications’effectsonnorepinephrineincreasebloodpressureandheartrate,constrictbloodvessels,increasebloodglucose,andopenupbreathingpassages.

Whatarethepossibleconsequencesofstimulantmisuse?

Aswithotherdrugsinthestimulantcategory,suchascocaine,itispossibleforpeopletobecomedependentonoraddictedtoprescriptionstimulants.Withdrawalsymptomsassociatedwithdiscontinuingstimulantuseincludefatigue,depression,anddisturbedsleeppatterns.Repeatedmisuseofsomestimulants(sometimeswithinashortperiod)canleadtofeelingsofhostilityorparanoia,orevenpsychosis. Further,takinghighdosesofastimulantmayresultindangerouslyhighbodytemperatureandanirregularheartbeat.Thereisalsothepotentialforcardiovascularfailureor

41

42–44

® ®

® ®

45

29

45

19

seizures.

CognitiveEnhancers

Thedramaticincreasesinstimulantprescriptionsoverthelast2decadeshaveledtotheirgreateravailabilityandtoincreasedriskfordiversionandnonmedicaluse. Whentakentoimproveproperlydiagnosedconditions,thesemedicationscangreatlyenhanceapatient’squalityoflife.However,becausemanyperceivethemtobegenerallysafeandeffective,prescriptionstimulantssuchasAdderall andModafinil arebeingmisusedmorefrequently.

Stimulantsincreasewakefulness,motivation,andaspectsofcognition,learning,andmemory.Somepeopletakethesedrugsintheabsenceofmedicalneedinanefforttoenhancementalperformance. Militarieshavelongusedstimulantstoincreaseperformanceinthefaceoffatigue,andtheUnitedStatesArmedForcesallowfortheiruseinlimitedoperationalsettings. Thepracticeisnowreportedbysomeprofessionalstoincreasetheirproductivity,byolderpeopletooffsetdecliningcognition,andbybothhighschoolandcollegestudentstoimprovetheiracademicperformance.

Nonmedicaluseofstimulantsforcognitiveenhancementposespotentialhealthrisks,includingaddiction,cardiovascularevents,andpsychosis.Theuseofpharmaceuticalsforcognitiveenhancementhasalsosparkeddebateovertheethicalimplicationsofthepractice.Issuesoffairnessariseifthosewithaccessandwillingnesstotakethesedrugshaveaperformanceedgeoverothers,andimplicitcoerciontakesplaceifacultureofcognitiveenhancementgivestheimpressionthatapersonmusttakedrugsinordertobecompetitive.

45

46

® ®

47

48

47,49

20

Areprescriptiondrugssafetotakewhenpregnant?

Prescriptionmedicationstakenbyapregnantwomancancauseherbabytodevelopdependence,whichcanresultinwithdrawalsymptomsafterbirth,knownasneonatalabstinencesyndrome(NAS).Thiscanrequireaprolongedstayinneonatalintensivecareand,inthecaseofopioids,treatmentwithmedication(see"SexandGenderDifferencesinSubstanceUseDisorderTreatment"intheNIDA'sSubstanceUseinWomenResearchReport).Womenshouldconsultwiththeirdoctorstodeterminewhichmedicationstheycancontinuetakingduringpregnancy.

Opioidpainmedicationsrequireparticularattention;risingratesofNAShavebeenassociatedwithincreasesintheprescriptionofopioidsforpaininpregnantwomen.NASassociatedwithopioiduse(heroinorprescriptionopioids)increasedfivefoldfrom2000to2012,withahigherrateofincreaseinmorerecentyears.

©iStock.com/Photobac

50,51

21

Howcanprescriptiondrugmisusebeprevented?

Clinicians,Patients,andPharmacists

Physicians,theirpatients,andpharmacistsallcanplayaroleinidentifyingandpreventingnonmedicaluseofprescriptiondrugs.

Clinicians.Morethan80percentofAmericanshadcontactwithahealthcareprofessionalinthepastyear ,placingdoctorsinauniquepositiontoidentifynonmedicaluseofprescriptiondrugsandtakemeasurestopreventtheescalationofapatient’smisusetoasubstanceusedisorder.Byaskingaboutalldrugs,physicianscanhelptheirpatientsrecognizethataproblemexists,provideorreferthemtoappropriatetreatment,andsetrecoverygoals.Evidence-basedscreeningtoolsfornonmedicaluseofprescriptiondrugscanbeincorporatedintoroutinemedicalvisits(seetheNIDAMEDwebpageforresourcesformedicalandhealthprofessionals).Doctorsshouldalsotakenoteofrapidincreasesintheamountofmedicationneededorfrequent,unscheduledrefillrequests.Doctorsshouldbealerttothefactthatthosemisusingprescriptiondrugsmayengagein"doctorshopping"—movingfromprovidertoprovider—inanefforttoobtainmultipleprescriptionsfortheirdrug(s)ofchoice.

Prescriptiondrugmonitoringprograms(PDMPs),state-runelectronicdatabasesusedtotracktheprescribinganddispensingofcontrolledprescriptiondrugstopatients,arealsoimportanttoolsforpreventingandidentifyingprescriptiondrugmisuse.Whileresearchregardingtheimpactoftheseprogramsiscurrentlymixed,theuseofPDMPsinsomestateshasbeenassociatedwithlowerratesofopioidprescribingandoverdose ,thoughissuesofbestpractices,easeofuse,andinteroperabilityremaintoberesolved.

In2015,thefederalgovernmentlaunchedaninitiativedirectedtowardreducingopioidmisuseandoverdose,inpartbypromotingmorecautiousandresponsibleprescribingofopioidmedications.Inlinewiththeseefforts,

52

53–56

22

in2016theCentersforDiseaseControlandPrevention(CDC)publisheditsCDCGuidelineforPrescribingOpioidsforChronicPaintoestablishclinicalstandardsforbalancingthebenefitsandrisksofchronicopioidtreatment.Preventingorstoppingnonmedicaluseofprescriptiondrugsisanimportantpartofpatientcare.However,certainpatientscanbenefitfromprescriptionstimulants,sedatives,oropioidpainrelievers.Therefore,physiciansshouldbalancethelegitimatemedicalneedsofpatientswiththepotentialriskformisuseandrelatedharms.

Patients.Patientscantakestepstoensurethattheyuseprescriptionmedicationsappropriatelyby:

followingthedirectionsasexplainedonthelabelorbythepharmacist

beingawareofpotentialinteractionswithotherdrugsaswellasalcohol

neverstoppingorchangingadosingregimenwithoutfirstdiscussingitwiththedoctor

neverusinganotherperson’sprescription,andnevergivingtheirprescriptionmedicationstoothers

storingprescriptionstimulants,sedatives,andopioidssafely

Additionally,patientsshouldproperlydiscardunusedorexpiredmedicationsbyfollowingU.S.FoodandDrugAdministration(FDA)guidelinesorvisitingU.S.DrugEnforcementAdministrationcollectionsites. Inadditiontodescribingtheirmedicalproblem,patientsshouldalwaysinformtheirhealthcareprofessionalsaboutalltheprescriptions,over-the-countermedicines,anddietaryandherbalsupplementstheyaretakingbeforetheyobtainanyothermedications.

27

57

23

Pharmacists.Pharmacistscanhelppatientsunderstandinstructionsfortakingtheirmedications.Inaddition,bybeingwatchfulforprescriptionfalsificationsoralterations,pharmacistscanserveasthefirstlineofdefenseinrecognizingproblematicpatternsinprescriptiondruguse.Somepharmacieshavedevelopedhotlinestoalertotherpharmaciesintheregionwhentheydetectafraudulentprescription.Alongwithphysicians,pharmacistscanusePDMPstohelptrackopioid-prescribingpatternsinpatients.

MedicationFormulationandRegulation

Manufacturersofprescriptiondrugscontinuetoworkonnewformulationsofopioidmedications,knownasabuse-deterrentformulations(ADF),whichincludetechnologiesdesignedtopreventpeoplefrommisusingthembysnortingorinjection.Approachescurrentlybeingusedorstudiedforuseinclude:

©iStock.com/HconQ

24

physicalorchemicalbarriersthatpreventthecrushing,grinding,ordissolvingofdrugproducts

agonist/antagonistcombinationsthatcauseanantagonist(whichwillcounteractthedrugeffect)tobereleasediftheproductismanipulated

aversivesubstancesthatareaddedtocreateunpleasantsensationsifthedrugistakeninawayotherthandirected

deliverysystemssuchaslong-actinginjectionsorimplantsthatslowlyreleasethedrugovertime

newmolecularentitiesorprodrugsthatattachachemicalextensiontoadrugthatrendersitinactiveunlessitistakenorally

SeveralADFopioidsareonthemarket,andtheFDAhasalsocalledforthedevelopmentofADFstimulants. WhileADFopioidshavebeenshowntodecreasetheillicitvalueofadrug,intheabsenceofreduceddemand,theycanshiftusetootherformulations. Medicationregulationhasbeenshowntobeeffectiveindecreasingtheprescribingofopioidmedications.In2014,theDrugEnforcementAdministrationmovedhydrocodoneproductsfromscheduleIIItothemorerestrictivescheduleII,whichresultedinadecreaseinhydrocodoneprescribingthatdidnotresultinanyattendantincreasesintheprescribingofotheropioids.

DevelopmentofSaferMedications

Thedevelopmentofeffective,nonaddictingpainmedicationsisapublichealthpriority.Agrowingnumberofolderadultsandanincreasingnumberofinjuredmilitaryservicemembersaddtotheurgencyoffindingnewtreatments.Researchersareexploringalternativetreatmentapproachesthattargetothersignalingsystemsinthebodysuchastheendocannabinoidsystem,whichisalsoinvolvedinpain. Moreresearchisalsoneededtobetterunderstandeffectivechronicpainmanagement,includingidentifyingfactorsthatpredisposesomepatientstosubstanceusedisordersanddevelopingmeasurestopreventthenonmedicaluseofprescriptionmedications.

58

58

30

59

25

Howcanprescriptiondrugaddictionbetreated?

Yearsofresearchhaveshownthatsubstanceusedisordersarebraindisordersthatcanbetreatedeffectively.Treatmentmusttakeintoaccountthetypeofdrugusedandtheneedsoftheindividual.Successfultreatmentmayneedtoincorporateseveralcomponents,includingdetoxification,counseling,andmedications,whenavailable.Multiplecoursesoftreatmentmaybeneededforthepatienttomakeafullrecovery.

Thetwomaincategoriesofdrugaddictiontreatmentarebehavioraltreatments(suchascontingencymanagementandcognitive-behavioraltherapy)andmedications.Behavioraltreatmentshelppatientsstopdrugusebychangingunhealthypatternsofthinkingandbehavior;teachingstrategiestomanagecravingsandavoidcuesandsituationsthatcouldleadtorelapse;or,insomecases,providingincentivesforabstinence.Behavioraltreatments,whichmaytaketheformofindividual,family,orgroupcounseling,alsocanhelppatientsimprovetheirpersonalrelationshipsandtheirabilitytofunctionatworkandinthecommunity.

Addictiontoprescriptionopioidscanadditionallybetreatedwithmedicationsincludingbuprenorphine,methadone,andnaltrexone[see"Medication-AssistedTreatment(MAT)"below].Thesedrugscancountertheeffectsofopioidsonthebrainorrelievewithdrawalsymptomsandcravings,helpingthepatientavoidrelapse.Medicationsforthetreatmentofaddictionareadministeredincombinationwithpsychosocialsupportsorbehavioraltreatments,knownasmedication-assistedtreatment(MAT).

Medication-AssistedTreatment(MAT)

Naltrexoneisanantagonistmedicationthatpreventsotheropioidsfrombindingtoandactivatingopioidreceptors.Itisusedtotreatoverdoseandaddiction.Aninjectable,long-actingformofnaltrexone(Vivitrol )canbeausefultreatmentchoiceforpatientswhodonothavereadyaccessto

60

60

61

®

26

healthcareorwhostrugglewithtakingtheirmedicationsregularly.

Methadoneisasyntheticopioidagonistthatpreventswithdrawalsymptomsandrelievesdrugcravingsbyactingonthesamebraintargetsasotheropioidssuchasheroin,morphine,andopioidpainmedications.Ithasbeenusedsuccessfullyformorethan40yearstotreatheroinaddictionbutisgenerallyonlyavailablethroughspeciallylicensedopioidtreatmentprograms.

Buprenorphineisapartialopioidagonist—itbindstotheopioidreceptorbutonlypartiallyactivatesit—thatcanbeprescribedbycertifiedphysiciansinanofficesetting.Likemethadone,itcanreducecravingsandiswelltoleratedbypatients.InMay2016,theU.S.FoodandDrugAdministration(FDA)approvedtheNIDA-supporteddevelopmentofanimplantableformulationofbuprenorphineandaoncemonthlybuprenorphineinjectioninNovember2017.Bothwillgivebuprenorphine-stabilizedpatientsgreateaseintreatmentadherence.

ANIDAstudycomparingtheeffectivenessofabuprenorphine/naloxonecombinationandanextendedreleasenaltrexoneformulationontreatingopioidusedisorderhasfoundthatbothmedicationsaresimilarlyeffectiveintreatingopioidusedisorderoncetreatmentisinitiated.Becausenaltrexonerequiresfulldetoxification,initiatingtreatmentamongactiveopioiduserswasmoredifficultwiththismedication.However,oncedetoxificationwascomplete,thenaltrexoneformulationhadasimilareffectivenessasthebuprenorphine/naloxonecombination.

Therehasbeenapopularmisconceptionthatmedicationswithagonistactivity,suchasmethadoneorbuprenorphine,replaceoneaddictionwithanother.Thisisnotthecase.Opioidusedisorderisassociatedwithimbalancesinbraincircuitsthatmediatereward,decision-making,impulsecontrol,learning,andotherfunctions.Thesemedicationsrestorebalancetothesebraincircuits,preventingopioidwithdrawalandrestoringthepatienttoanormalaffectivestatetoallowforeffectivepsychosocialtreatmentandsocialfunctioning.

27

WhileMATisthestandardofcarefortreatingopioidusedisorder,farfewerpeoplereceiveMATthancouldpotentiallybenefitfromit.Notallpeoplewithopioidusedisorderseektreatment.Evenwhentheyseektreatment,theywillnotnecessarilyreceiveMAT.Themostrecenttreatmentadmissionsdataavailableshowthatonly18percentofpeopleadmittedforprescriptionopioidusedisorderhaveatreatmentplanthatincludesMAT.However,evenifthenationwideinfrastructurewereoperatingatcapacity,between1.3and1.4millionmorepeoplehaveopioidusedisorderthancouldcurrentlybetreatedwithMATduetolimitedavailabilityofopioidtreatmentprogramsthatcandispensemethadoneandtheregulatorylimitonthenumberofpatientsthatphysicianscantreatwithbuprenorphine.CoordinatedeffortsareunderwaynationwidetoexpandaccesstoMAT,includingarecentincreaseinthebuprenorphinepatientlimitfrom100patientsto275forqualifiedphysicianswhorequestthehigherlimit.

TheNIDAissupportingresearchneededtodeterminethemosteffectivewaystoimplementMAT.Forexample,recentworkhasshownthatbuprenorphinemaintenancetreatmentismoreeffectivethantaperingpatientsoffofbuprenorphine. Also,startingbuprenorphinetreatmentwhenapatientisadmittedtotheemergencydepartment,suchasforanoverdose,isamoreeffectivewaytoengageapatientintreatmentthanreferralorbriefintervention. Finally,datahaveshownthattreatmentwithmethadone,buprenorphine,ornaltrexoneforincarceratedindividualsimprovespost-releaseoutcomes.

ReversinganOpioidOverdosewithNaloxone

Theopioidoverdose-reversaldrugnaloxoneisanopioidantagonistthatcanrapidlyrestorenormalrespirationtoapersonwhohasstoppedbreathingasaresultofoverdoseonprescriptionopioidsorheroin.Naloxonecanbeusedbyemergencymedicalpersonnel,firstresponders,andbystanders.Formoreinformation,visittheNIDA'swebpageonnaloxone.

62

63

64

65

66

67–69

28

TreatingAddictiontoCNSDepressants

Patientsaddictedtocentralnervoussystem(CNS)depressantssuchastranquilizers,sedatives,andhypnoticsshouldnotattempttostoptakingthemontheirown.Withdrawalsymptomsfromthesedrugscanbesevereand—inthecaseofcertainmedications—potentiallylife-threatening.ResearchontreatingaddictiontoCNSdepressantsissparse;however,patientswhoaredependentonthesemedicationsshouldundergomedicallysuperviseddetoxificationbecausethedosagetheytakeshouldbetaperedgradually.Inpatientoroutpatientcounselingcanhelpindividualsthroughthisprocess.Cognitive-behavioraltherapy,whichfocusesonmodifyingthepatient’sthinking,expectations,andbehaviorswhileincreasingskillsforcopingwithvariouslifestressors,hasalsobeenusedsuccessfullytohelpindividualsadapttodiscontinuingbenzodiazepines.

OftenCNSdepressantmisuseoccursinconjunctionwiththeuseofotherdrugs(polydruguse),suchasalcoholoropioids. Insuchcases,thetreatmentapproachshouldaddressthemultipleaddictions.

Atthistime,therearenoFDA-approvedmedicationsfortreatingaddictiontoCNSdepressants,thoughresearchisongoinginthisarea.

29

70

71

29

TreatingAddictiontoPrescriptionStimulants

TreatmentofaddictiontoprescriptionstimulantssuchasAdderall andConcerta isbasedonbehavioraltherapiesthatareeffectivefortreatingcocaineandmethamphetamineaddiction.Atthistime,therearenoFDA-approvedmedicationsfortreatingstimulantaddiction.TheNIDAissupportingresearchinthisarea.

Dependingonthepatient,thefirststepsintreatingprescriptionstimulantaddictionmaybetotaperthedrugdosageandattempttoeasewithdrawalsymptoms.Behavioraltreatmentmaythenfollowthedetoxificationprocess(see"BehavioralTherapies"intheNIDA'sPrinciplesofDrugAddictionTreatment:AResearch-BasedGuide).

®

®

41

30

WherecanIgetfurtherinformationaboutprescriptiondrugmisuse?

Tolearnmoreaboutprescriptiondrugsandotherdrugs,visittheNIDAwebsiteatdrugabuse.govorcontacttheDrugPubsResearchDisseminationCenterat877-NIDA-NIH(877-643-2644;TTY/TDD:240-645-0228).

TheNIDA'swebsiteincludes:

informationondrugsandrelatedhealthconsequences

NIDApublications,news,andevents

resourcesforhealthcareprofessionals

fundinginformation(includingprogramannouncementsanddeadlines)

internationalactivities

linkstorelatedwebsites(accesstowebsitesofmanyotherorganizationsinthefield)

informationinSpanish(enespañol)

NIDAwebsitesandwebpages

drugabuse.gov

teens.drugabuse.gov

easyread.drugabuse.gov

drugabuse.gov/drugs-abuse/prescription-drugs-cold-medicines

researchstudies.drugabuse.gov

irp.drugabuse.gov

Forphysicianinformation

31

NIDAMED:drugabuse.gov/nidamed

Otherwebsites

Informationaboutprescriptiondrugmisuseisalsoavailablethroughthefollowingwebsites:

SubstanceAbuseandMentalHealthServicesAdministration:samhsa.gov

U.S.DrugEnforcementAdministration:dea.gov

MonitoringtheFuture:monitoringthefuture.org

PartnershipforDrug-FreeKids:drugfree.org/drug-guide

ThispublicationisavailableforyouruseandmaybereproducedinitsentiretywithoutpermissionfromtheNIDA.Citationofthesourceisappreciated,usingthefollowinglanguage:Source:NationalInstituteonDrugAbuse;NationalInstitutesofHealth;U.S.DepartmentofHealthandHumanServices.

32

References

1. SubstanceAbuseCenterforBehavioralHealthStatisticsandQuality.Resultsfromthe2016NationalSurveyonDrugUseandHealth:DetailedTables.SAMHSA.https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.htm.PublishedSeptember7,2017.AccessedMarch7,2018.

2. BlancoC,AldersonD,OgburnE,etal.Changesintheprevalenceofnon-medicalprescriptiondruguseanddrugusedisordersintheUnitedStates:1991–1992and2001–2002.DrugAlcoholDepend.2007;90(2-3):252-260.doi:10.1016/j.drugalcdep.2007.04.005.

3. SubstanceAbuseandMentalHealthServicesAdministration,CenterforBehavioralHealthStatisticsandQuality.TreatmentEpisodeDataSet(TEDS):2003-2013.NationalAdmissionstoSubstanceAbuseTreatmentServices.2015.http://www.samhsa.gov/data/sites/default/files/2013_Treatment_Episode_Data_Set_National/2013_Treatment_Episode_Data_Set_National.pdf

4. CenterforBehavioralHealthStatisticsandQuality(CBHSQ).DrugAbuseWarningNetwork:2011:SelectedTablesofNationalEstimatesofDrug-RelatedEmergencyDepartmentVisits.Rockville,MD:SubstanceAbuseandMentalHealthServicesAdministration;2013.

5. JonesCM,McAninchJK.EmergencyDepartmentVisitsandOverdoseDeathsFromCombinedUseofOpioidsandBenzodiazepines.AmJPrevMed.2015;49(4):493-501.doi:10.1016/j.amepre.2015.03.040.

6. RuddRA,AleshireN,ZibbellJE,GladdenRM.IncreasesinDrugandOpioidOverdoseDeaths-UnitedStates,2000-2014.MMWRMorbMortalWklyRep.2016;64(50-51):1378-1382.doi:10.15585/mmwr.mm6450a3.

7. CDC.CDCWonderMultipleCauseofDeath.http://wonder.cdc.gov/wonder/help/mcd.html.

8. CentersforDiseaseControlandPrevention(CDC).Vitalsigns:overdosesofprescriptionopioidpainrelievers–UnitedStates,1999-2008.MMWRMorbMortalWklyRep.2011;60(43):1487-1492.

9. ManchikantiL,FellowsB,AilinaniH,PampatiV.Therapeuticuse,abuse,

33

andnonmedicaluseofopioids:aten-yearperspective.PainPhysician.2010;13(5):401-435.

10. DaniulaityteR,FalckR,CarlsonRG.“I’mnotafraidofthoseonesjust‘causethey’vebeenprescribed”:Perceptionsofriskamongillicitusersofpharmaceuticalopioids.IntJDrugPolicy.2012;23(5):374-384.doi:10.1016/j.drugpo.2012.01.012.

11. WebsterPC.Oxycodoneclassactionlawsuitfiled.CanMedAssocJ.2012;184(7):E345-E346.doi:10.1503/cmaj.109-4158.

12. QatoDM,AlexanderGC,ContiRM,JohnsonM,SchummP,LindauST.UseofPrescriptionandOver-the-counterMedicationsandDietarySupplementsAmongOlderAdultsintheUnitedStates.JAMA.2008;300(24):2867.doi:10.1001/jama.2008.892.

13. CentersforDiseaseControlandPrevention(CDC).Vitalsigns:overdosesofprescriptionopioidpainrelieversandotherdrugsamongwomen--UnitedStates,1999-2010.MMWRMorbMortalWklyRep.2013;62(26):537-542.

14. MiechR,JohnstonL,O’MalleyPM,KeyesKM,HeardK.PrescriptionOpioidsinAdolescenceandFutureOpioidMisuse.Pediatrics.2015;136(5):e1169-e1177.doi:10.1542/peds.2015-1364.

15. Johnston,L.D.;Meich,R.A.,O’Malley,P.M.;Bachman,J.G.;Schulenberg,J.E.;andPatrick,M.E.MonitoringtheFutureNationalResultsonAdolescentDrugUse:1975-2017.Overview,KeyFindingsonAdolescentDrugUse.AnnArbor:InstituteforSocialResearch,TheUniversityofMichigan.Availableat:www.monitoringthefuture.org

16. McCabeSE,TeterCJ,BoydCJ.Illicituseofprescriptionpainmedicationamongcollegestudents.DrugAlcoholDepend.2005;77(1):37-47.doi:10.1016/j.drugalcdep.2004.07.005.

17. BoydCJ,EstebanMcCabeS,TeterCJ.MedicalandnonmedicaluseofprescriptionpainmedicationbyyouthinaDetroit-areapublicschooldistrict.DrugAlcoholDepend.2006;81(1):37-45.doi:10.1016/j.drugalcdep.2005.05.017.

18. McCabeSE.MedicalandNonmedicalUseofPrescriptionOpioidsAmongHighSchoolSeniorsintheUnitedStates.ArchPediatrAdolescMed.2012;166(9):797.doi:10.1001/archpediatrics.2012.85.

34

19. YoungAM,GloverN,HavensJR.NonmedicalUseofPrescriptionMedicationsAmongAdolescentsintheUnitedStates:ASystematicReview.JAdolescHealth.2012;51(1):6-17.doi:10.1016/j.jadohealth.2012.01.011.

20. WangR,ChenL,FanL,etal.IncidenceandEffectsofPolypharmacyonClinicalOutcomeamongPatientsAged80+:AFive-YearFollow-UpStudy.PloSOne.2015;10(11):e0142123.doi:10.1371/journal.pone.0142123.

21. CottoJH,DavisE,DowlingGJ,ElcanoJC,StatonAB,WeissSRB.Gendereffectsondruguse,abuse,anddependence:aspecialanalysisofresultsfromtheNationalSurveyonDrugUseandHealth.GendMed.2010;7(5):402-413.doi:10.1016/j.genm.2010.09.004.

22. CentersforDiseaseControlandPrevention.CDCVitalSignsPrescriptionPainkillerOverdoses:AGrowingEpidemic,EspeciallyAmongWomen.July2013.http://www.cdc.gov/vitalsigns/PrescriptionPainkillerOverdoses/index.html.

23. RonanMV,HerzigSJ.HospitalizationsRelatedToOpioidAbuse/DependenceAndAssociatedSeriousInfectionsIncreasedSharply,2002-12.HealthAff(Millwood).2016;35(5):832-837.doi:10.1377/hlthaff.2015.1424.

24. JonesCM,PaulozziLJ,MackKA,CentersforDiseaseControlandPrevention(CDC).Alcoholinvolvementinopioidpainrelieverandbenzodiazepinedrugabuse-relatedemergencydepartmentvisitsanddrug-relateddeaths-UnitedStates,2010.MMWRMorbMortalWklyRep.2014;63(40):881-885.

25. PentelP.ToxicityofOver-the-CounterStimulants.JAMAJAmMedAssoc.1984;252(14):1898.doi:10.1001/jama.1984.03350140044023.

26. GutsteinH,AkilH.OpioidAnalgesics.In:Goodman&Gilman’sthePharmacologicalBasisofTherapeutics.11thed.McGraw-Hill;2006:547-590.

27. DowellD,HaegerichTM,ChouR.CDCGuidelineforPrescribingOpioidsforChronicPain-UnitedStates,2016.MMWRRecommRepMorbMortalWklyRepRecommRepCentDisControl.2016;65(1):1-49.doi:10.15585/mmwr.rr6501e1.

28. LeeM,SilvermanSM,HansenH,PatelVB,ManchikantiL.A

35

comprehensivereviewofopioid-inducedhyperalgesia.PainPhysician.2011;14(2):145-161.

29. HartCL,KsirC.Drugs,Society&HumanBehavior.15thed.NewYork,NY:McGraw-Hill;2013.

30. JonesCM,LuriePG,ThrockmortonDC.EffectofUSDrugEnforcementAdministration’sReschedulingofHydrocodoneCombinationAnalgesicProductsonOpioidAnalgesicPrescribing.JAMAInternMed.January2016.doi:10.1001/jamainternmed.2015.7799.

31. MedlinePlus.Oxycodone.March2016.https://www.nlm.nih.gov/medlineplus/druginfo/meds/a682132.html.

32. MedlinePlus.Oxymorphone.March2016.https://www.nlm.nih.gov/medlineplus/druginfo/meds/a610022.html#why.

33. CiceroTJ,EllisMS.Abuse-DeterrentFormulationsandthePrescriptionOpioidAbuseEpidemicintheUnitedStates:LessonsLearnedFromOxyContin.JAMAPsychiatry.2015;72(5):424-430.doi:10.1001/jamapsychiatry.2014.3043.

34. O’BrienCP,DackisC.PrinciplesofthePharmacotherapyofAddictiveDisorders.In:NeurobiologyofMentalIllness.Third.OxfordUniversityPress;2009:867-880.

35. O’BrienCP.DrugAddictionandDrugAbuse.In:Goodman&Gilman’sthePharmacologicalBasisofTherapeutics.11thed.McGraw-Hill;2006:607-627.

36. InstituteofMedicine(U.S.),ed.RelievingPaininAmerica:ABlueprintforTransformingPrevention,Care,Education,andResearch.Washington,D.C:NationalAcademiesPress;2011.

37. ChouR,TurnerJA,DevineEB,etal.TheEffectivenessandRisksofLong-TermOpioidTherapyforChronicPain:ASystematicReviewforaNationalInstitutesofHealthPathwaystoPreventionWorkshop.AnnInternMed.2015;162(4):276.doi:10.7326/M14-2559.

38. HypnoticsandSedatives.In:Goodman&Gilman’sthePharmacologicalBasisofTherapeutics.11thed.McGraw-Hill;2006:401-427.

39. GunjaN.TheClinicalandForensicToxicologyofZ-drugs.JMedToxicol.

36

2013;9(2):155-162.doi:10.1007/s13181-013-0292-0.

40. SellersEM.Alcohol,barbiturateandbenzodiazepinewithdrawalsyndromes:clinicalmanagement.CMAJCanMedAssocJ.1988;139(2):113-120.

41. CiccaroneD.StimulantAbuse:Pharmacology,Cocaine,Methamphetamine,Treatment,AttemptsatPharmacotherapy.PrimCareClinOffPract.2011;38(1):41-58.doi:10.1016/j.pop.2010.11.004.

42. CampionEW,ScammellTE.Narcolepsy.NEnglJMed.2015;373(27):2654-2662.doi:10.1056/NEJMra1500587.

43. SantoshPJ,SattarS,CanagaratnamM.Efficacyandtolerabilityofpharmacotherapiesforattention-deficithyperactivitydisorderinadults.CNSDrugs.2011;25(9):737-763.doi:10.2165/11593070-000000000-00000.

44. CorpSA,GitlinMJ,AltshulerLL.Areviewoftheuseofstimulantsandstimulantalternativesintreatingbipolardepressionandmajordepressivedisorder.JClinPsychiatry.2014;75(9):1010-1018.doi:10.4088/JCP.13r08851.

45. WestfallTC,WestfallDP.AdrenergicAgonistsandAntagonists.In:Goodman&Gilman’sthePharmacologicalBasisofTherapeutics.11thed.McGraw-Hill;2006:237-295.

46. McCabeSE,WestBT.MedicalandNonmedicalUseofPrescriptionStimulants:ResultsFromaNationalMulticohortStudy.JAmAcadChildAdolescPsychiatry.2013;52(12):1272-1280.doi:10.1016/j.jaac.2013.09.005.

47. SchelleKJ,FaulmüllerN,CaviolaL,HewstoneM.Attitudestowardpharmacologicalcognitiveenhancement–areview.FrontSystNeurosci.2014;8.doi:10.3389/fnsys.2014.00053.

48. CaldwellJA,CaldwellJL.Fatigueinmilitaryaviation:anoverviewofUSmilitary-approvedpharmacologicalcountermeasures.AviatSpaceEnvironMed.2005;76(7Suppl):C39-C51.

49. HymanSE.CognitiveEnhancement:PromisesandPerils.Neuron.2011;69(4):595-598.doi:10.1016/j.neuron.2011.02.012.

50. ToliaVN,PatrickSW,BennettMM,etal.IncreasingIncidenceofthe

37

NeonatalAbstinenceSyndromeinU.S.NeonatalICUs.NEnglJMed.April2015:150426153016002.doi:10.1056/NEJMsa1500439.

51. PatrickSW,DavisMM,LehmannCU,CooperWO.Increasingincidenceandgeographicdistributionofneonatalabstinencesyndrome:UnitedStates2009to2012.JPerinatolOffJCalifPerinatAssoc.2015;35(8):650-655.doi:10.1038/jp.2015.36.

52. NationalCenterforHealthStatistics,CDC.AmbulatoryCareUseandPhysicianofficevisits.2014.http://www.cdc.gov/nchs/fastats/physician-visits.htm.

53. RasubalaL,PernapatiL,VelasquezX,BurkJ,RenY-F.ImpactofaMandatoryPrescriptionDrugMonitoringProgramonPrescriptionofOpioidAnalgesicsbyDentists.NarendranR,ed.PLOSONE.2015;10(8):e0135957.doi:10.1371/journal.pone.0135957.

54. JohnsonH,PaulozziL,PorucznikC,MackK,HerterB,HalJohnsonConsultingandDivisionofDiseaseControlandHealthPromotion,FloridaDepartmentofHealth.Declineindrugoverdosedeathsafterstatepolicychanges-Florida,2010-2012.MMWRMorbMortalWklyRep.2014;63(26):569-574.

55. RutkowL,ChangH-Y,DaubresseM,WebsterDW,StuartEA,AlexanderGC.EffectofFlorida’sPrescriptionDrugMonitoringProgramandPillMillLawsonOpioidPrescribingandUse.JAMAInternMed.2015;175(10):1642-1649.doi:10.1001/jamainternmed.2015.3931.

56. FranklinG,SabelJ,JonesCM,etal.AComprehensiveApproachtoAddressthePrescriptionOpioidEpidemicinWashingtonState:MilestonesandLessonsLearned.AmJPublicHealth.2015;105(3):463-469.doi:10.2105/AJPH.2014.302367.

57. FDA.DisposalofUnusedMedicines:WhatYouShouldKnow.October2015.http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/EnsuringSafeUseofMedicine/SafeDisposalofMedicines/ucm186187.htm

58. SimonK,WorthySL,BarnesMC,TarbellB.Abuse-deterrentformulations:transitioningthepharmaceuticalmarkettoimprovepublichealthandsafety.TherAdvDrugSaf.2015;6(2):67-79.doi:10.1177/2042098615569726.

59. MaldonadoR,BañosJE,CabañeroD.Theendocannabinoidsystemand

38

neuropathicpain.Pain.2016;157Suppl1:S23-S32.doi:10.1097/j.pain.0000000000000428.

60. NIDA.PrinciplesofDrugAddictionTreatment:AResearch-BasedGuide(ThirdEdition).December2012.https://d14rmgtrwzf5a.cloudfront.net/sites/default/files/podat_1.pdf.

61. VolkowND,FriedenTR,HydePS,ChaSS.Medication-AssistedTherapies—TacklingtheOpioid-OverdoseEpidemic.NEnglJMed.2014;370(22):2063-2066.doi:10.1056/NEJMp1402780.

62. SubstanceAbuseandMentalHealthServicesAdministration,CenterforBehavioralHealthStatistics,andQuality.TreatmentEpisodeDataSet(TEDS)2002-2012:NationalAdmissionstoSubstanceAbuseTreatmentServices.2014.http://www.samhsa.gov/data/sites/default/files/TEDS2012N_Web.pdf.

63. JonesCM,CampopianoM,BaldwinG,McCance-KatzE.NationalandStateTreatmentNeedandCapacityforOpioidAgonistMedication-AssistedTreatment.AmJPublicHealth.2015;105(8):e55-e63.doi:10.2105/AJPH.2015.302664.

64. ObamaAdministrationTakesMoreActionstoAddressthePrescriptionOpioidandHeroinEpidemic.July2016.https://www.whitehouse.gov/the-press-office/2016/07/05/obama-administration-takes-more-actions-address-prescription-opioid-and.

65. FiellinDA,SchottenfeldRS,CutterCJ,MooreBA,BarryDT,O’ConnorPG.Primarycare-basedbuprenorphinetapervsmaintenancetherapyforprescriptionopioiddependence:arandomizedclinicaltrial.JAMAInternMed.2014;174(12):1947-1954.doi:10.1001/jamainternmed.2014.5302.

66. D’OnofrioG,O’ConnorPG,PantalonMV,etal.EmergencyDepartment–InitiatedBuprenorphine/NaloxoneTreatmentforOpioidDependence:ARandomizedClinicalTrial.JAMA.2015;313(16):1636.doi:10.1001/jama.2015.3474.

67. GordonMS,KinlockTW,SchwartzRP,FitzgeraldTT,O’GradyKE,VocciFJ.Arandomizedcontrolledtrialofprison-initiatedbuprenorphine:prisonoutcomesandcommunitytreatmententry.DrugAlcoholDepend.2014;142:33-40.doi:10.1016/j.drugalcdep.2014.05.011.

39

68. KinlockTW,GordonMS,SchwartzRP,O’GradyK,FitzgeraldTT,WilsonM.Arandomizedclinicaltrialofmethadonemaintenanceforprisoners:resultsat1-monthpost-release.DrugAlcoholDepend.2007;91(2-3):220-227.doi:10.1016/j.drugalcdep.2007.05.022.

69. LeeJD,FriedmannPD,KinlockTW,etal.Extended-ReleaseNaltrexonetoPreventOpioidRelapseinCriminalJusticeOffenders.NEnglJMed.2016;374(13):1232-1242.doi:10.1056/NEJMoa1505409.

70. DarkerCD,SweeneyBP,BarryJM,FarrellMF,Donnelly-SwiftE.Psychosocialinterventionsforbenzodiazepineharmfuluse,abuseordependence.CochraneDatabaseSystRev.2015;5:CD009652.doi:10.1002/14651858.CD009652.pub2.

71. JonesJD,MogaliS,ComerSD.Polydrugabuse:Areviewofopioidandbenzodiazepinecombinationuse.DrugAlcoholDepend.2012;125(1-2):8-18.doi:10.1016/j.drugalcdep.2012.07.004.